Scoop has an Ethical Paywall
Drug-resistant Candida auris - Expert Reaction
There were alarming headlines from the
US over the weekend about a type of yeast that has been
causing serious illness in hospital
patients.
Candida
auris can cause invasive infections and often does not
respond to commonly-used antifungal drugs, according to the Centers for Disease
Control and Prevention.
The SMC asked experts about the fungi and New Zealand's preparedness.
Professor Michael
Baker, Professor of Public Health, University of Otago,
Wellington,
comments:
"Reports about
the rise of Candida auris are worrying as this
organism is frequently resistant to multiple antifungal
drugs. One unusual aspect of this pathogen is that it is a
fungus, whereas most of the concerns about growing
antimicrobial resistance (AMR) have been about bacteria.
Since it was first detected and named in 2009 this organism
has spread globally. A small number of cases have been
detected in Australia, largely in people who have arrived
from overseas. There do not appear to have been any reported
cases in New Zealand to date, but it is almost inevitable
that it will be seen here.
"Candida auris infections mainly occur in health care facilities (nosocomial infections) where they may cause prolonged outbreaks. It adds to the growing number of nosocomial infections that worsen outcomes for seriously ill patients, increasing mortality and the length of hospital stays. Control measures are broadly similar to those used for other resistant organisms in such settings, such as methicillin-resistant Staphylococcus aureus (MRSA).
"New Zealand microbiologists and infectious disease specialists are aware of this organism and how to diagnose, treat and control it. However, it will inevitably add to the complexity and costs of managing nosocomial infections. New Zealand is very unlikely to experience the kind of secrecy described in the New York Times articlewhere there were apparently delays in reporting such infections to protect the commercial interests of some hospitals.
"The rise of Candida auris illustrates what AMR looks like. It will probably not be a single catastrophic event like a pandemic, but more a series of reminders that we cannot rely on antimicrobial drugs to work in the same way as they have in the past. In most cases, these infections will be a particular threat to the most vulnerable, such as those will underlying illness, immune-suppressive treatment, and the very young and elderly.
"Given the inevitability of increasing AMR threats, it is important to keep asking whether New Zealand is well prepared. Are our diagnostic and surveillance capabilities and response systems sufficiently developed and organised to respond in a highly coordinated way? Hopefully, this is one of the issues that the current Health and Disability System Review can consider."
No conflict of interest.
Dr Heather
Hendrickson, senior lecturer in molecular biosciences,
Massey University,
comments:
"Essentially,
Candida auris is a yeast, not a bacterium. It has
cells that are structurally more like ours (have a nucleus
and mitochondria).
"It is frightening to read about because, like other superbugs, it is becoming increasingly resistant to the antimicrobials that doctors use to treat it and it is easily spread. This is also an emerging infectious organism that was first recognised in Japan in 2009 and appears to be springing up in many places around the globe simultaneously, but the isolates found in different locations are generally closely related to one another. This suggests that something environmental may be stimulating the transition of these to become serious threats in hospitals and in human patients, where they were not found previous to 2009.
"Importantly for the public in New Zealand, this is not on the list of notifiable infectious diseases here. This means that it is not publicly reported to the Medical Officer of Health if it is recognised in a hospital or lab.
"I am not aware of any reason that people in New Zealand should be overly concerned at this time. However, this is a good time to take a look at our monitoring practices and ensure that we are using the molecular tests that would allow us to identify this organism if it appeared clinically in our hospitals. Rapidly and accurately distinguishing C. auris from other infectious fungal pathogens is an important part of handling an infectious microorganism like this one."
No conflict of interest.
ends
Science Media Centre NZ
Our aim is to promote accurate, evidence-based reporting on science and technology by helping the media work more closely with the scientific community.
The Science Media Centre is New Zealand's only trusted, independent source of information for the media on all issues related to science. Thousands of news stories providing context from and quoting New Zealand researchers have been published as a direct result of our work.
John Mazenier: Gaffer Tape And Glue Delivering New Zealand’s Mission Critical Services
Earthquake Commission: Ivan Skinner Award Winner Inspired By Real-life Earthquake Experience
Reserve Bank: Consultation Opens On A Digital Currency For New Zealand
NIWA: Ship Anchors May Cause Extensive And Long-lasting Damage To The Seafloor, According To New Research
New Zealand Customs Service: A Step Forward For Simpler Trade Between New Zealand And Singapore
Horizon Research: 68% Say Make Banks Offer Fraud Protection
